Magnesium-zinc-calcium-vitamin D co-supplementation improves hormonal profiles, biomarkers of inflammation and oxidative stress in women with polycystic ovary syndrome: A randomized, double-blind, placebo-controlled trial by Maktabi, M. et al.
Magnesium-Zinc-Calcium-Vitamin D Co-supplementation
Improves Hormonal Profiles, Biomarkers of Inflammation
and Oxidative Stress inWomen with Polycystic Ovary Syndrome:
a Randomized, Double-Blind, Placebo-Controlled Trial
Maryam Maktabi1 & Mehri Jamilian1 & Zatollah Asemi2
Received: 2 June 2017 /Accepted: 21 June 2017 /Published online: 1 July 2017
Abstract Data on the effects of magnesium-zinc-calcium-
vitamin D co-supplementation on hormonal profiles, biomarkers
of inflammation, and oxidative stress among women with poly-
cystic ovary syndrome (PCOS) are scarce. The objective of this
study was to assess the effects of magnesium-zinc-calcium-
vitamin D co-supplementation on hormonal profiles, biomarkers
of inflammation, andoxidativestress inwomenwithPCOS.Sixty
PCOSwomenwere randomized into twogroups and treatedwith
100 mg magnesium, 4 mg zinc, 400 mg calcium plus 200 IU
vitamin D supplements (n = 30), or placebo (n = 30) twice a day
for 12 weeks. Hormonal profiles, biomarkers of inflammation,
and oxidative stress were assessed at baseline and at end-of-treat-
ment.After the12-week intervention, comparedwith theplacebo,
magnesium-zinc-calcium-vitaminDco-supplementationresulted
in significant reductions in hirsutism (−2.4 ± 1.2 vs. −0.1 ± 0.4,
P < 0.001), serum high sensitivity C-reactive protein (−0.7 ± 0.8
vs. +0.2 ± 1.8 mg/L, P < 0.001), and plasma malondialdehyde
(−0.4 ± 0.3 vs. +0.2 ± 1.0 μmol/L, P = 0.01), and a significant
increase in plasma total antioxidant capacity concentrations
(+46.6 ± 66.5 vs. −7.7 ± 130.1 mmol/L, P = 0.04). We failed to
find any significant effect ofmagnesium-zinc-calcium-vitaminD
co-supplementationonfreeandrogen index,andotherbiomarkers
of inflammation and oxidative stress. Overall, magnesium-zinc-
calcium-vitamin D co-supplementation for 12 weeks among
PCOS women had beneficial effects on hormonal profiles, bio-
markers of inflammation, and oxidative stress.
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Introduction
Polycystic ovary syndrome (PCOS) is a frequent gynecolog-
ical endocrine disorder of women in the childbearing age and
is associated with infertility, menstrual irregularities, and bio-
chemical or clinical changes of hyperandrogenism [1].
Approximately, 6–12% of premenopausal women depending
on the diagnostic criteria used are affected by this disease [2].
In several previous studies [3, 4], it reported that subjects with
PCOS had significantly higher levels of high sensitivity C-
reactive protein (hs-CRP). Increased levels of hs-CRP were
associated with fat mass, hyperinsulinemia, and insulin resis-
tance in PCOS [5]. Different studies in PCOS women have
hinted that insulin resistance plays an important role in the
pathophysiology of metabolic syndrome, and that this can
induce an increase in biomarkers of oxidative stress and reac-
tive oxygen species (ROS) production by leukocytes [6, 7].
Weight loss and lifestyle change, such as increased physi-
cal activity, are the first-line treatment in the management of
PCOS [8]. Recently, the role of minerals, including magne-
sium, zinc and calcium, and vitamin D in the pathogenesis of
many metabolic diseases, such as PCOS, has been examined
[9, 10]. In addition, few studies have reported that mean zinc
concentrations in PCOS women are lower than healthy wom-
en [11], while, others demonstrated higher levels of zinc in
PCOS [9]. We have previously shown that vitamin D-K-
calcium co-supplementation for 8 weeks among subjects with
PCOS had beneficial effects on serum dehydroepiandroster-
one sulfate (DHEAS), free testosterone, and biomarkers of
oxidative stress, but did not affect inflammatory markers
[12]. In addition, in a study by Nielsen et al. [13], it was
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observed that taking 320 mg/day of magnesium supplements
for 7 weeks improved inflammatory factors in elderly people.
Also, calcium and vitamin D co-supplementation in subjects
with gestational diabetes had beneficial effects on biomarkers
of oxidative stress, but unchanged inflammatory markers [14].
However, among healthy middle-aged overweight subjects,
supplementation with 250 mg/day of magnesium as magne-
sium oxide for 8 weeks did not affect inflammatory factors
[15]. In addition, no significant change in inflammatory
markers and biomarkers of oxidative stress was observed fol-
lowing 18-month supplementation with fortified milk contain-
ing 1000 mg/day of calcium and 800 IU/day of vitamin D
among healthy subjects [16].
Calcium and vitamin D co-supplementation have earlier
been used by other researchers. Their co-supplementations
may be more efficient than single supplementation. In addi-
tion, few previous studies have exhibited that joint calcium
and vitamin D supplementation might have a strong synergis-
tic effect on metabolic status. For instance, Tabesh et al. [17]
observed joint calcium-vitamin D supplementation compared
with single supplementation improved systemic inflammation
in vitamin D-insufficient individuals with type 2 diabetes
mellitus. Furthermore, we have previously shown that com-
bined calcium and vitamin D intake compared with calcium or
vitamin D only for 8 weeks among PCOS patients had bene-
ficial effects on metabolic status [18, 19]. Magnesium intake
may improve metabolic profiles through effects of its antago-
nism to calcium and to participate in protein synthesis and
transmembrane ion transport [20]. In addition, calcium and
vitamin D intake might affect inflammation and oxidative
stress through their effects on activity increase of antioxidant
enzymes [21] and inhibiting synthesis of inflammatory cyto-
kines [22]. According to our knowledge, data on the effects of
magnesium-zinc-calcium-vitamin D co-supplementation on
hormonal profiles, biomarkers of inflammation, and oxidative
stress in subjects with PCOS are scarce. Therefore, we hy-
pothesized that magnesium-zinc-calcium-vitamin D intake
might affect metabolic status of PCOS population. We inves-
tigated this aim by conducting the effects of magnesium-zinc-
calcium-vitamin D co-supplementation on hormonal profiles,
markers of inflammation, and oxidative stress in women with
PCOS.
Subjects and Methods
Trial Design and Participants
This randomized double-blind placebo-controlled clinical trial
was performed among patients who were referred to the
Research and Clinical Center for Infertility at the Kosar clinic
affiliated to Arak University of Medical Sciences (AUMS),
Arak, Iran, between January 2017 and April 2017. Inclusion
criteria were subjects with PCOS according to the Rotterdam
criteria [23] and age range 18–40 years. All participants at-
tending the center were first examined by the study gynecol-
ogist and after diagnosis of PCOS in all subjects; they were
instructed to fill hirsutism ormodified Ferriman Gallwey (mF-
G) scoring form validated for the Iranian population [24]. The
research was approved by the research ethics committee of
AUMS. Smokers, intake of magnesium, zinc, calcium and/
or vitamin D supplements within the last 3 months, pregnant
women, other common causes of hyperandrogenism and/or
anovulation, including Cushing’s syndrome, androgen-
secreting tumors, hyperprolactinemia and thyroid dysfunc-
tion, and not living in Arak area were excluded in the study.
Study Design
Forty PCOS women were randomized into two groups and
treated with 100 mg magnesium, 4 mg zinc, 400 mg calcium
plus 200 IU vitamin D supplements (n = 30), or placebo
(n = 30) twice a day for 12 weeks. Quality control of
magnesium-zinc-calcium-vitamin D tablet was conducted in
the laboratory of Food and Drug Administration in Tehran,
Iran, by high-performance liquid chromatography (for vitamin
D) and atomic absorption spectroscopy (for magnesium, zinc,
and calcium) methods, respectively. Following quality con-
trol, we observed that the amount of magnesium, zinc, calci-
um, and vitamin D in the prescribed tablets was at the range of
95–110 mg, 3.8–4.4 mg, 380–440 mg, and 190–210 IU, re-
spectively. Shape and size of supplements and placebo tablets
were similar and manufactured by Vitane (Wolfratshausen,
Germany) and Barij Essence Pharmaceuticals (Kashan,
Iran), respectively. All participants were advised to maintain
their routine dietary habits, not to change other lifestyle fac-
tors, including physical activity during the study. All women
completed 3-day food records and three physical activity re-
cords as metabolic equivalents at weeks 0, 3, 6, 9, and 12 of
the treatment.
Treatment Adherence
To evaluate the compliance, subjects were asked to bring the
medication container. To ensure adherence, participants re-
ceived a short message on their cell phones to intake the sup-
plements daily.
Anthropometric Measures
At baseline and end-of-trial, all subjects underwent standard
anthropometric measurements: height and weight (Seca,
Hamburg, Germany). Body mass index (BMI) was calculated
as weight in kilograms divided by height in meters squared.
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Assessment of Outcomes
Weconsidered hormonal profiles as primary outcomes, and bio-
markers of inflammation and biomarkers of oxidative stress as
secondary outcomes. Ten-milliliter fasting blood samples were
collected before and after the 12-week treatment at Arak refer-
ence laboratory, Arak, Iran. Commercial kits were used to quan-
tify serum magnesium, zinc, and calcium concentrations (Pars
Azmun, Tehran, Iran). All inter- and intra-assay coefficient var-
iances (CVs) for magnesium, zinc, and calcium were less than
5%. Serum 25-hydroxyvitamin D levels were determined by a
commercial ELISA kit (IDS, Boldon, UK) with inter- and intra-
assay CVs of 4.4 to 6.6%, respectively. Serum total testosterone
with inter- and intra-assayCVs of 3.9 to 5.7% and sex hormone-
binding globulin (SHBG) with inter- and intra-assay CVs of 3.4
to 5.0% were determined by using commercial kits (DiaMetra,
Milano, Italy). Free androgen index (FAI) was calculated as the
ratio of total testosterone to SHBG. Serum hs-CRP values were
quantified using anELISAkit (LDN,Nordhorn,Germany)with
inter- and intra-assayCVs of 4.4 to 6.6%, respectively. The plas-
manitric oxide (NO)by theGriessmethod [25], total antioxidant
capacity (TAC)by theuseof the ferric reducingantioxidantpow-
ermethod developed byBenzie andStrain [26], total glutathione
(GSH) using the method of Beutler et al. [27], and
malondialdehyde (MDA) levels by the thiobarbituric acid reac-
tive substance spectrophotometric test [28] were determined.
CVs for plasma NO, TAC, GSH, and MDAwere 1.0, 1.1, 2.7,
and 3.4%, respectively.
Randomization
Randomization assignment was conducted using computer-
generated random numbers. Randomization and allocation
concealment were done from the researchers and participants
and were carried out by a trained staff at the gynecology clinic.
Another person, who was not involved in the intervention and
not aware of random sequences, assigned patients to the num-
bered bottles of capsules.
Statistical Methods
To calculate the sample size, we used the standard formula
suggested for clinical trials by considering type one error (α)
of 0.05 and type two error (β) of 0.20 (power = 80%). Based
on a previous study [29], we used 0.11 ng/mL as SD and
0.09 ng/mL as the difference in mean (d) of total testosterone
concentrations as primary variable. Based on this, we needed
25 subjects in each group. Considering a dropout of five sub-
jects per group, we calculated to have 30 subjects per group.
TheKolmogorov-Smirnov testwasapplied tocontrol thenor-
mal distribution of variables. Independent sample t test was used
to establish changes in anthropometric measures and dietary in-
takes between the two groups. To determine the effects of
magnesium-zinc-calcium-vitamin D co-supplementation on
hormonal profiles, biomarkers of inflammation, and oxidative
stress, we used one-way repeatedmeasures analysis of variance.
Adjustment for changes in baseline values of biochemical vari-
ables, age, and baseline BMI was performed by analysis of co-
variance. P < 0.05 were considered statistically significant. All
statistical analyses were conducted using the Statistical Package
for Social Science version 18 (SPSS Inc., Chicago, IL, USA).
Results
From 65 subjects who were recruited in our study (5 subjects
were excluded from the study because of not meeting inclu-
sion criteria), 60 participants in each group completed the trial
(Fig. 1). On average, higher than 90% of supplements were
consumed in both groups throughout the study.
Meanage,height,baseline, andend-of-trial ofweight andBMI
were not significantly different between the two groups (Table 1).
According to the 3-day dietary records taken throughout
the intervention, no significant changes was observed between
the two groups in terms of macro- and micro-nutrient intakes
(data not shown).
After the 12-week intervention, compared with the placebo,
magnesium-zinc-calcium-vitaminD co-supplementation signif-
icantly increased serum magnesium (+0.1 ± 0.1 vs.
−0.1 ± 0.3 mg/dL, P = 0.002), calcium (+0.4 ± 0.3 vs.
−0.01 ± 0.6 mg/dL, P = 0.001), and 25-OH-vitamin D
(+7.9 ± 8.4 vs. +0.1 ± 8.4 ng/mL, P < 0.001). In addition, com-
paredwith the placebo,magnesium-zinc-calcium-vitaminD co-
supplementation resulted in significant reductions in hirsutism
(−2.4 ± 1.2 vs.−0.1 ± 0.4,P< 0.001), serumhs-CRP (−0.7 ± 0.8
vs. +0.2±1.8mg/L,P<0.001) andplasmaMDA(−0.4±0.3 vs.
+0.2±1.0μmol/L,P=0.01), anda significant increase inplasma
TAC concentrations (+46.6 ± 66.5 vs. −7.7 ± 130.1 mmol/L,
P = 0.04) (Table 2). We failed to find any significant effect of
magnesium-zinc-calcium-vitamin D co-supplementation on
FAI, and other biomarkers of inflammation and oxidative stress.
There was a significant difference in baseline levels of TAC
(P = 0.009) and MDA (P < 0.001) between the two groups.
Therefore, we adjusted the analysis for baseline of biochemi-
cal variables, age, and baseline BMI. When we controlled the
analysis for baseline values of biochemical variables, age, and
baseline BMI, the difference in changes in TAC (P = 0.15) and
MDA (P = 0.95) between the two groups became non-signif-
icant, and serum zinc became significant (P = 0.01), while
other findings did not alter (Table 3).
Discussion
We found that magnesium-zinc-calcium-vitamin D co-
supplementation for 12 weeks among PCOS women had
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beneficial effects on hormonal profiles, biomarkers of inflam-
mation, and oxidative stress. To our knowledge, this study is
the first evaluating the effects of magnesium-zinc-calcium-
vitamin D co-supplementation on hormonal profiles, bio-
markers of inflammation, and oxidative stress among women
with PCOS.
Previous studies have supported that PCOS women are
susceptible to infertility, hirsutism, increased pro-
inflammatory factors, and oxidative stress [30, 31]. Prior stud-
ies have documented that vitamin D deficiency is a problem in
subjects with PCOS [32, 33]. Many observational studies
have reported a relationship between low levels of vitamin D
and features of the metabolic syndrome in PCOS women [34,
35]. One hypothesis relies on the regulatory effect of vitamin
D on the intracellular and extracellular calcium values that is
essential for insulin-mediated intracellular processes and may
have influence on insulin resistance [36]. Another theory in-
volves the stimulatory effect of vitamin D on gene expression
related to insulin receptors [37]. This study have indicated that
magnesium-zinc-calcium-vitamin D co-supplementation for
12 weeks in PCOS women led to a significant reduction in
hirsutism and total testosterone compared with the placebo,
but it did not affect SHBG and FAI. Data on the effects of
magnesium and zinc supplementation on female fertility and
hormonal pictures are scarce. We have previously reported
that vitamin D-K-calcium co-supplementation for 8 weeks
among women with PCOS resulted in a significant reduction
in free testosterone and DHEAS, but it did not influence other
hormonal profiles [12]. Furthermore, vitamin D and calcium
co-administration in PCOS women for 12 weeks was associ-
ated with a significant decrease in total testosterone and an-
drostenedione levels [16]. Firouzabadi et al. [38] demonstrat-
ed that taking 100,000 IU vitamin D for 6 months plus
1000 mg/day calcium among PCOS women resulted in im-
proved follicular maturation, regularity of menses, and
androgen-related symptoms especially in subjects with
Randomized (n=60)
Allocated to placebo (n=30)
Lost to follow-up (n=0)
Analyzed (n=30)
Allocated to intervention (n=30)
Lost to follow-up (n=0)
Analyzed (n=30)
Assessed for eligibility (n=65)
Excluded (n=5) 
- Not meeting inclusion criteria (n=2) 




























Fig. 1 Summary of patient flow
diagram
Table 1 General characteristics
of study participants Placebo group (n = 30) Magnesium-zinc-calcium-vitamin
D group (n = 30)
P1
Age (year) 24.8 ± 4.8 23.8 ± 5.7 0.48
Height (cm) 163.5 ± 5.3 164.0 ± 6.6 0.73
Weight at study baseline (kg) 68.3 ± 11.4 65.4 ± 11.8 0.32
Weight at end-of-trial (kg) 67.8 ± 11.8 64.8 ± 11.6 0.31
Weight change (kg) −0.5 ± 1.1 −0.6 ± 0.5 0.59
BMI at study baseline (kg/m2) 25.6 ± 4.8 24.2 ± 3.8 0.20
BMI at end-of-trial (kg/m2) 25.5 ± 4.9 24.0 ± 3.7 0.20
BMI change (kg/m2) −0.1 ± 0.4 −0.2 ± 0.2 0.58
Data are means ± SDs
1Obtained from independent-samples t test
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vitamin D deficiency. Direct/indirect effects of vitamin D and
calcium on the steroidogenesis pathway (ovarian and/or adre-
nal) may be mediated by reducing circulating androgens [16].
In addition, zinc element has been documented to inhibit 5 α-
reductase, which catalyzes the transformation of testosterone
to its non-aromatizable form, di-hydro testosterone (DHT)
[39]. Thus, increased circulating levels of zinc may also help
to decrease PCOS-associated hyperandrogenemia through
inhibiting transformation of testosterone to its active form
DHT [9].
The current study indicated that magnesium-zinc-calcium-
vitamin D co-supplementation among patients with PCOS for
12 weeks was associated with a significant decrease in serum
hs-CRP, but did not affect plasma NO levels. In line with our
Table 3 Adjusted changes in
metabolic profile of the patients
with polycystic ovary syndrome
Placebo group (n = 30) Magnesium-zinc-calcium-vitamin
D group (n = 30)
P1
Magnesium (mg/dL) −0.1 ± 0.03 0.1 ± 0.03 0.01
Zinc (mg/dL) −1.7 ± 1.5 3.7 ± 1.5 0.01
Calcium (mg/dL) −0.01 ± 0.1 0.4 ± 0.1 0.001
25-OH-vitamin D (ng/mL) −0.2 ± 1.1 8.1 ± 1.1 <0.001
Total testosterone (ng/mL) 0.03 ± 0.1 −0.2 ± 0.1 0.04
SHBG (nmol/L) 2.8 ± 4.0 9.9 ± 4.0 0.21
FAI −0.04 ± 0.02 −0.02 ± 0.02 0.40
mF-G scores −0.2 ± 0.2 −2.3 ± 0.2 <0.001
hs-CRP (mg/L) 0.2 ± 0.1 −0.8 ± 0.1 <0.001
NO (μmol/L) 2.6 ± 1.5 4.0 ± 1.5 0.54
TAC (mmol/L) −0.6 ± 19.2 39.6 ± 19.2 0.15
GSH (μmol/L) 63.2 ± 15.4 55.3 ± 15.4 0.72
MDA (μmol/L) −0.1 ± 0.1 −0.1 ± 0.1 0.95
All values are means ± SEs. Values are adjusted for baseline values, age, and BMI at baseline
FAI free androgen index, GSH total glutathione, hs-CRP high-sensitivity C-reactive protein, mF-G modified
Ferriman Gallwey, MDA malondialdehyde, NO nitric oxide, SHBG sex hormone-binding globulin, TAC total
antioxidant capacity
1 Obtained from ANCOVA
Table 2 Metabolic profiles at baseline and after the 12-week intervention in subjects with polycystic ovary syndrome
Placebo group (n = 30) Magnesium-zinc-calcium-vitamin D group (n = 30) P1
Baseline End-of-trial Change Baseline End-of-trial Change
Magnesium (mg/dL) 1.6 ± 0.3 1.5 ± 0.2 −0.1 ± 0.3 1.5 ± 0.2 1.6 ± 0.2 0.1 ± 0.1 0.002
Zinc (mg/dL) 101.0 ± 14.9 100.1 ± 13.6 −0.9 ± 7.6 106.1 ± 17.9 109.1 ± 18.5 3.0 ± 8.8 0.06
Calcium (mg/dL) 9.3 ± 0.5 9.3 ± 0.8 −0.01 ± 0.6 9.5 ± 0.5 9.9 ± 0.5 0.4 ± 0.3 0.001
25-OH-vitamin D (ng/mL) 10.8 ± 4.6 10.9 ± 4.5 0.1 ± 0.5 10.1 ± 4.9 18.0 ± 10.3 7.9 ± 8.4 <0.001
Total testosterone (ng/mL) 1.4 ± 0.9 1.5 ± 0.9 0.1 ± 0.4 1.6 ± 0.6 1.4 ± 0.5 −0.2 ± 0.5 0.02
SHBG (nmol/L) 41.6 ± 17.3 45.4 ± 16.9 3.8 ± 19.8 43.2 ± 28.2 52.2 ± 34.8 8.9 ± 25.1 0.37
FAI 0.15 ± 0.17 0.12 ± 0.07 −0.03 ± 0.16 0.20 ± 0.15 0.16 ± 0.16 −0.02 ± 0.14 0.86
mF-G scores 12.6 ± 3.9 12.5 ± 3.9 −0.1 ± 0.4 14.3 ± 3.8 11.9 ± 3.1 −2.4 ± 1.2 <0.001
hs-CRP (mg/L) 3.1 ± 2.1 3.3 ± 1.8 0.2 ± 0.8 3.7 ± 1.6 3.0 ± 1.2 −0.7 ± 0.8 <0.001
NO (μmol/L) 47.4 ± 9.9 50.0 ± 10.5 2.5 ± 12.8 46.6 ± 5.8 50.7 ± 6.4 4.1 ± 7.3 0.57
TAC (mmol/L) 881.6 ± 165.0 873.9 ± 189.3 −7.7 ± 130.1 794.9 ± 59.3 841.5 ± 75.8 46.6 ± 66.5 0.04
GSH (μmol/L) 508.7 ± 96.6 562.8 ± 90.1 54.2 ± 128.5 491.2 ± 75.8 555.5 ± 73.0 64.3 ± 104.7 0.74
MDA (μmol/L) 2.2 ± 0.6 2.4 ± 0.9 0.2 ± 1.0 2.8 ± 0.2 2.4 ± 0.2 −0.4 ± 0.3 0.01
All values are means ± SDs
FAI free androgen index,GSH total glutathione, hs-CRP high-sensitivity C-reactive protein,mF-Gmodified Ferriman Gallwey,MDAmalondialdehyde,
NO nitric oxide, SHBG sex hormone-binding globulin, TAC total antioxidant capacity
1P values represent the time × group interaction (computed by analysis of the one-way repeated measures ANOVA)
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study, results of a meta-analysis study demonstrated that mag-
nesium supplementation among subjects with inflammation
decreased CRP levels [40]. Similarly, supplementation with
30 mg/day of zinc as zinc gluconate for 8 weeks among obese
women decreased inflammatory cytokines [41]. We have pre-
v ious ly shown tha t ca lc ium and vi tamin D co-
supplementation for 8 weeks among overweight and vitamin
D-deficient subjects with PCOS had beneficial effects on se-
rum hs-CRP, but did not influence plasma NO levels [18].
However, taking magnesium as magnesium oxide at dosage
of 250 mg/day for 8 weeks among overweight women did not
significantly attenuate inflammatory markers [15]. The ad-
ministration of rosuvastatin with or without zinc supplements
at dosage of 30 mg/day in subjects with atherosclerosis for
4 months did not influence hs-CRP levels [42]. Previous stud-
ies have shown that increased inflammatory cytokines play an
important role in insulin resistance and the vascular inflam-
mation process through multiple actions [43, 44]. Anti-
inflammatory effects of magnesium may be due to its antago-
nism to calcium, the ion playing an important role in inflam-
mation [45]. Moreover, zinc intake may be associated with the
regulation of nuclear factor-κB activation via anti-
inflammatory proteins A20 and peroxisome proliferator acti-
vated receptor-α signaling pathway [46]. Less production of
parathyroid hormone following supplementation of calcium
and vitamin D supplements may result in decreased produc-
tion of inflammatory factors [47].
We demonstrated that magnesium-zinc-calcium-vitamin D
co-supplementation among women with PCOS for 12 weeks
resulted in a significant elevation in plasma TAC and a signif-
icant reduction in plasma MDA levels, but unchanged plasma
GSH levels. Supporting our study, magnesium supplementa-
tion at dosage of 200–270 mg/day as magnesium citrate for
4 weeks in asthmatic children could exert antioxidant activity
and affect the glutathione redox system [48]. Furthermore,
zinc supplementation (100 mg/day) for 8 weeks increased
circulating levels of antioxidant status, such as TAC and
GSH, and MDA concentrations decreased in hemodialysis
patients [49]. Also, in an experimental study on zinc-
deficient rats, zinc administration resulted in lower MDA con-
centrations, and higher GSH levels [50]. We have previously
demonstrated that taking calcium (1000 mg/day) plus vitamin
D (50,000 IU/weekly) supplements for 8 weeks among PCOS
women had beneficial effects on biomarkers of oxidative
stress [18]. Oxidative stress may play an important role in
the pathophysiology of patients with PCOS and the develop-
ment of its complications, because free radicals and bio-
markers of oxidative stress maymodify the structure and func-
tion of proteins and lipids due to glycoxidation and peroxida-
tion [51]. Combined magnesium-zinc-calcium-vitamin D
might have a better effect on metabolic profiles than magne-
sium, zinc, calcium, or vitamin D alone. For instance, in a
study by Tabesh et al. [17], it was observed that joint
calcium-vitamin D3 supplementation than calcium or vitamin
D3 only had more beneficial effects on systemic inflammation
through decreasing interleukin 6 and tumor necrosis factor-
alpha concentrations in vitamin D-insufficient subjects with
type 2 diabetes mellitus. Magnesium intake might reduce ox-
idative stress through decreasing ROS production [52] and
increasing glutathione-peroxidase activity [53]. Furthermore,
zinc intake may cause decreased formation of ·OH from hy-
drogen peroxide through the antagonism of redox-active tran-
sition metals, such as iron and copper [54], and increased
production of some substances that are the ultimate antioxi-
dant such as metallothioneins [55]. Calcium intake may affect
oxidative stress through calcium transport and signaling line
[56]. In addition, improvement in the cellular GSH concentra-
tions and a decrease in ROS, and pro-inflammatory factors by
vitamin D supplements may explain its beneficial effects on
oxidative stress [57].
The current study had some limitations. Due to limited
funding, we could not evaluate the effects of magnesium-
zinc-calcium-vitamin D co-supplementation on gene expres-
sion related to inflammation and oxidative stress. It is also
difficult to conclude when four products (magnesium-zinc-
calcium-vitamin D) are being used against placebo.
Therefore, further studies are necessary with single supple-
mentation for each comparison with co-supplementation to
determine the beneficial effects of each on hormonal profiles,
biomarkers of inflammation, and oxidative stress.
Overall, magnesium-zinc-calcium-vitamin D co-
supplementation for 12 weeks among PCOS women had ben-
eficial effects on hormonal profiles, biomarkers of inflamma-
tion, and oxidative stress.
Acknowledgements The current study was supported by a grant from
the Vice-chancellor for Research, AUMS, and Iran.
Authors’ Contributions ZA contributed in conception, design, statis-
tical analysis, and drafting of the manuscript. MM and MJ contributed in
data collection and manuscript drafting. ZA supervised the study.
Compliance with Ethical Standards
Conflict of Interest The authors declare that they have no conflict of
interest.
References
1. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz
BO (2004) The prevalence and features of the polycystic ovary
syndrome in an unselected population. J Clin Endocrinol Metab
89:2745–2749
2. Clark NM, Podolski AJ, Brooks ED, Chizen DR, Pierson RA,
Lehotay DC, Lujan ME (2014) Prevalence of polycystic ovary
syndrome phenotypes using updated criteria for polycystic ovarian
morphology: an assessment of over 100 consecutive women self-
26 Maktabi et al.
reporting features of polycystic ovary syndrome. Reprod Sci 21:
1034–1043
3. Diamanti-Kandarakis E, Paterakis T, Alexandraki K, Piperi C,
Aessopos A, Katsikis I, Katsilambros N, Kreatsas G, Panidis D
(2006) Indices of low-grade chronic inflammation in polycystic ovary
syndrome and the beneficial effect of metformin. Hum Reprod 21:
1426–1431
4. Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B
(2005) Central fat excess in polycystic ovary syndrome: relation to
low-grade inflammation and insulin resistance. J Clin Endocrinol
Metab 90:6014–6021
5. Glintborg D (2016) Endocrine and metabolic characteristics in
polycystic ovary syndrome. Dan Med J 63
6. Gonzalez F, Rote NS, Minium J, Kirwan JP (2006) Reactive oxy-
gen species-induced oxidative stress in the development of insulin
resistance and hyperandrogenism in polycystic ovary syndrome. J
Clin Endocrinol Metab 91:336–340
7. Victor VM, Rocha M, Banuls C, Sanchez-Serrano M, Sola E,
Gomez M, Hernandez-Mijares A (2009) Mitochondrial complex I
impairment in leukocytes from polycystic ovary syndrome patients
with insulin resistance. J Clin Endocrinol Metab 94:3505–3512
8. Costello MF, Misso ML, Wong J, Hart R, Rombauts L, Melder A,
Norman RJ, Teede HJ (2012) The treatment of infertility in polycystic
ovarysyndrome:abriefupdate.AustNZJObstetGynaecol52:400–403
9. Chakraborty P, Ghosh S, Goswami SK, Kabir SN, Chakravarty B,
Jana K (2013) Altered trace mineral milieu might play an
aetiological role in the pathogenesis of polycystic ovary syndrome.
Biol Trace Elem Res 152:9–15
10. Nandi A, Sinha N, Ong E, Sonmez H, Poretsky L (2016) Is there a
role for vitamin D in human reproduction? Horm Mol Biol Clin
Invest 25:15–28
11. Guler I, Himmetoglu O, Turp A, Erdem A, Erdem M, Onan MA,
Taskiran C, Taslipinar MY, Guner H (2014) Zinc and homocysteine
levels in polycystic ovarian syndrome patients with insulin resis-
tance. Biol Trace Elem Res 158:297–304
12. Razavi M, Jamilian M, Karamali M, Bahmani F, Aghadavod E,
Asemi Z (2016) The effects of vitamin D-K-calcium co-
supplementation on endocrine, inflammation, and oxidative stress
biomarkers in vitamin D-deficient women with polycystic ovary
syndrome: a randomized, double-blind, placebo-controlled trial.
Horm Metab Res 48:446–451
13. Nielsen FH, Johnson LK, Zeng H (2010) Magnesium supplemen-
tation improves indicators of low magnesium status and inflamma-
tory stress in adults older than 51 years with poor quality sleep.
Magnes Res 23:158–168
14. Asemi Z, Karamali M, Esmaillzadeh A (2014) Effects of calcium-
vitamin D co-supplementation on glycaemic control, inflammation
and oxidative stress in gestational diabetes: a randomised placebo-
controlled trial. Diabetologia 57:1798–1806
15. Moslehi N, VafaM, Rahimi-Foroushani A,GolestanB (2012) Effects
of oral magnesium supplementation on inflammatory markers in
middle-aged overweight women. J ResMed Sci 17:607–614
16. Pal L, Berry A, Coraluzzi L, Kustan E, Danton C, Shaw J, Taylor H
(2012) Therapeutic implications of vitamin D and calcium in over-
weight women with polycystic ovary syndrome. Gynecol
Endocrinol 28:965–968
17. Tabesh M, Azadbakht L, Faghihimani E, Esmaillzadeh A (2014)
Calcium-vitamin D cosupplementation influences circulating in-
flammatory biomarkers and adipocytokines in vitamin D-
insufficient diabetics: a randomized controlled clinical trial. J Clin
Endocrinol Metab 99:E2485–E2493
18. Foroozanfard F, Jamilian M, Bahmani F, Talaee R, Talaee N,
Hashemi T, Nasri K, Asemi Z, Esmaillzadeh A (2015) Calcium
plus vitamin D supplementation influences biomarkers of inflam-
mation and oxidative stress in overweight and vitamin D-deficient
women with polycystic ovary syndrome: a randomized double-
blind placebo-controlled clinical trial. Clin Endocrinol 83:888–894
19. Asemi Z, Foroozanfard F, Hashemi T, Bahmani F, Jamilian M,
Esmaillzadeh A (2015) Calcium plus vitamin D supplementation
affects glucose metabolism and lipid concentrations in overweight
and obese vitamin D deficient women with polycystic ovary syn-
drome. Clin Nutr 34:586–592
20. Almoznino-Sarafian D, Berman S, Mor A, Shteinshnaider M,
Gorelik O, Tzur I, Alon I, Modai D, Cohen N (2007) Magnesium
and C-reactive protein in heart failure: an anti-inflammatory effect
of magnesium administration? Eur J Nutr 46:230–237
21. Hajsadeghi S, Hejrati M, Moghadami S, Rismantab S, Namiranian
P (2012) Dilated cardiomyopathy in two patients with xeroderma
pigmentosum disease: a case report. Acta Med Iran 50:147–150
22. Sandhu MS, Casale TB (2010) The role of vitamin D in asthma.
Ann Allergy Asthma Immunol 105:191–199 quiz 200-192, 217
23. Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop
group (2004) Revised 2003 consensus on diagnostic criteria and
long-term health risks related to polycystic ovary syndrome. Fertil
Steril 81:19–25
24. Ramezani Tehrani F, Minooee S, Azizi F (2014) Validation of a
simplified method to assess hirsutism in the Iranian population.
Eur J Obstet Gynecol Reprod Biol 174:91–95
25. Tatsch E, Bochi GV, Pereira Rda S, Kober H, Agertt VA, de
CamposMM,Gomes P, DuarteMM,Moresco RN (2011) A simple
and inexpensive automated technique for measurement of serum
nitrite/nitrate. Clin Biochem 44:348–350
26. Benzie IF, Strain JJ (1996) The ferric reducing ability of plasma
(FRAP) as a measure of Bantioxidant power^: the FRAP assay.
Anal Biochem 239:70–76
27. Beutler E, Gelbart T (1985) Plasma glutathione in health and in
patients with malignant disease. J Lab Clin Med 105:581–584
28. Janero DR (1990) Malondialdehyde and thiobarbituric acid-
reactivity as diagnostic indices of lipid peroxidation and
peroxidative tissue injury. Free Radic Biol Med 9:515–540
29. GargG,KachhawaG,RamotR,KhadgawatR,TandonN,SreenivasV,
Kriplani A, Gupta N (2015) Effect of vitamin D supplementation on
insulin kinetics and cardiovascular risk factors in polycystic ovarian
syndrome: a pilot study. Endocr Connect 4:108–116
30. Asemi Z, Samimi M, Tabassi Z, Shakeri H, Sabihi SS,
Esmaillzadeh A (2014) Effects of DASH diet on lipid profiles
and biomarkers of oxidative stress in overweight and obese women
with polycystic ovary syndrome: a randomized clinical trial.
Nutrition 30:1287–1293
31. Jamilian M, Razavi M, Fakhrie Kashan Z, Ghandi Y, Bagherian T,
Asemi Z (2015)Metabolic response to selenium supplementation in
women with polycystic ovary syndrome: a randomized, double-
blind, placebo-controlled trial. Clin Endocrinol 82:885–891
32. Kotsa K, YavropoulouMP, Anastasiou O, Yovos JG (2009) Role of
vitamin D treatment in glucose metabolism in polycystic ovary
syndrome. Fertil Steril 92:1053–1058
33. Yildizhan R, Kurdoglu M, Adali E, Kolusari A, Yildizhan B, Sahin
HG, Kamaci M (2009) Serum 25-hydroxyvitamin D concentrations
in obese and non-obese women with polycystic ovary syndrome.
Arch Gynecol Obstet 280:559–563
34. Wehr E, Pilz S, Schweighofer N, Giuliani A, Kopera D, Pieber TR,
Obermayer-Pietsch B (2009) Association of hypovitaminosis D
with metabolic disturbances in polycystic ovary syndrome. Eur J
Endocrinol 161:575–582
35. Li HW, Brereton RE, Anderson RA, Wallace AM, Ho CK (2011)
Vitamin D deficiency is common and associated with metabolic risk
factors in patients with polycystic ovary syndrome. Metabolism 60:
1475–1481
36. Pittas AG, Lau J, Hu FB, Dawson-Hughes B (2007) The role of
vitamin D and calcium in type 2 diabetes. A systematic review and
meta-analysis. J Clin Endocrinol Metab 92:2017–2029
Magnesium-Zinc-Calcium-Vitamin D Co-supplementation and PCOS 27
37. Maestro B, Molero S, Bajo S, Davila N, Calle C (2002)
Transcriptional activation of the human insulin receptor gene by
1,25-dihydroxyvitamin D(3). Cell Biochem Funct 20:227–232
38. Firouzabadi R, Aflatoonian A, Modarresi S, Sekhavat L,
Mohammad Taheri S (2012) Therapeutic effects of calcium & vi-
tamin D supplementation in women with PCOS. Complement Ther
Clin Pract 18:85–88
39. Stamatiadis D, Bulteau-Portois MC, Mowszowicz I (1988)
Inhibition of 5 alpha-reductase activity in human skin by zinc and
azelaic acid. Br J Dermatol 119:627–632
40. Simental-Mendia LE, Sahebkar A, Rodriguez-Moran M, Zambrano-
Galvan G, Guerrero-Romero F (2017) Effect of magnesium supple-
mentation on plasma C-reactive protein concentrations: a systematic
review andmeta-analysis of randomized controlled trials. Curr Pharm
Des. doi:10.2174/1381612823666170525153605
41. Kim J, Ahn J (2014) Effect of zinc supplementation on inflamma-
tory markers and adipokines in young obese women. Biol Trace
Elem Res 157:101–106
42. Dias PC, Sena-Evangelista KC, Paiva MS, Ferreira DQ, Ururahy
MA, Rezende AA, Abdalla DS, Pedrosa LF (2014) The beneficial
effects of rosuvastatin are independent of zinc supplementation in
patients with atherosclerosis. J Trace Elem Med Biol 28:194–199
43. Jialal I, Devaraj S, Venugopal SK (2004) C-reactive protein: risk
marker or mediator in atherothrombosis? Hypertension 44:6–11
44. Wellen KE, Hotamisligil GS (2005) Inflammation, stress, and dia-
betes. J Clin Invest 115:1111–1119
45. Aneiros E, Philipp S, Lis A, Freichel M, Cavalie A (2005)
Modulation of Ca2+ signaling by Na+/Ca2+ exchangers in mast
cells. J Immunol 174:119–130
46. Bao B, Prasad AS, Beck FW, Fitzgerald JT, Snell D, Bao GW,
Singh T, Cardozo LJ (2010) Zinc decreases C-reactive protein, lipid
peroxidation, and inflammatory cytokines in elderly subjects: a po-
tential implication of zinc as an atheroprotective agent. Am J Clin
Nutr 91:1634–1641
47. Brandi L (2008) 1alpha(OH)D3 one-alpha-hydroxy-cholecalcifer-
ol—an active vitamin D analog. Clinical studies on prophylaxis and
treatment of secondary hyperparathyroidism in uremic patients on
chronic dialysis. Dan Med Bull 55:186–210
48. Bede O, Nagy D, Suranyi A, Horvath I, Szlavik M, Gyurkovits K
(2008)Effectsofmagnesiumsupplementationontheglutathioneredox
system in atopic asthmatic children. InflammRes 57:279–286
49. Mazani M, Argani H, Rashtchizadeh N, Ghorbanihaghjo A, Hamdi
A, Estiar MA, Nezami N (2013) Effects of zinc supplementation on
antioxidant status and lipid peroxidation in hemodialysis patients. J
Ren Nutr 23:180–184
50. Shaheen AA, el-Fattah AA (1995) Effect of dietary zinc on lipid
peroxidation, glutathione, protein thiols levels and superoxide dis-
mutase activity in rat tissues. Int J Biochem Cell Biol 27:89–95
51. Hyderali BN, Mala K (2015) Oxidative stress and cardiovascular
complications in polycystic ovarian syndrome. Eur J Obstet
Gynecol Reprod Biol 191:15–22
52. Liu YX, Guo YM,Wang Z (2007) Effect of magnesium on reactive
oxygen species production in the thigh muscles of broiler chickens.
Br Poult Sci 48:84–89
53. Boujelben M, Ghorbel F, Vincent C, Makni-Ayadi F, Guermazi F,
Croute F, El-Feki A (2006) Lipid peroxidation andHSP72/73 expres-
sion in rat following cadmium chloride administration: interactions of
magnesium supplementation. Exp Toxicol Pathol 57:437–443
54. Powell SR (2000) The antioxidant properties of zinc. J Nutr 130:
1447S–1454S
55. McCormick CC, Menard MP, Cousins RJ (1981) Induction of he-
patic metallothionein by feeding zinc to rats of depleted zinc status.
Am J Phys 240:E414–E421
56. Ermak G, Davies KJ (2002) Calcium and oxidative stress: from cell
signaling to cell death. Mol Immunol 38:713–721
57. Jain SK, Micinski D (2013) Vitamin D upregulates glutamate cys-
teine ligase and glutathione reductase, and GSH formation, and
decreases ROS and MCP-1 and IL-8 secretion in high-glucose ex-
posed U937monocytes. Biochem Biophys Res Commun 437:7–11
28 Maktabi et al.
